VIRI RSI Chart
Last 7 days
-12.2%
Last 30 days
-29.4%
Last 90 days
-7.7%
Trailing 12 Months
-66.4%
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Aug 21, 2023 | pridgen william | bought | 19,992 | 1.3037 | 15,335 | - |
Aug 17, 2023 | duncan gregory scott | bought | 31,245 | 1.2498 | 25,000 | chief executive officer |
Dec 08, 2022 | whitley richard james | sold | -466 | 0.2591 | -1,800 | - |
May 23, 2022 | walsh angela | bought | 9,150 | 4.575 | 2,000 | svp of finance |
May 23, 2022 | duncan gregory scott | bought | 33,900 | 4.52 | 7,500 | chief executive officer |
May 18, 2022 | whitley richard james | bought | 2,262 | 4.525 | 500 | - |
May 18, 2022 | pridgen william | bought | 1,084 | 4.5 | 241 | - |
May 17, 2022 | pridgen william | bought | 58,913 | 4.3802 | 13,450 | - |
Mar 29, 2022 | pridgen william | bought | 2,964 | 4.9408 | 600 | - |
Mar 23, 2022 | pridgen william | bought | 12,001 | 5.4627 | 2,197 | - |
Which funds bought or sold VIRI recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 13, 2024 | XTX Topco Ltd | sold off | -100 | -13,087 | - | -% |
May 13, 2024 | UBS Group AG | sold off | -100 | -1,495 | - | -% |
May 13, 2024 | GEODE CAPITAL MANAGEMENT, LLC | unchanged | - | -16,733 | 83,601 | -% |
May 13, 2024 | RENAISSANCE TECHNOLOGIES LLC | sold off | -100 | -119,000 | - | -% |
May 10, 2024 | GROUP ONE TRADING, L.P. | reduced | -41.99 | -4,154 | 3,886 | -% |
May 10, 2024 | WELLS FARGO & COMPANY/MN | added | 2.31 | -11.00 | 64.00 | -% |
May 10, 2024 | BlackRock Inc. | unchanged | - | -72.00 | 362 | -% |
May 10, 2024 | VANGUARD GROUP INC | unchanged | - | -20,032 | 100,076 | -% |
May 07, 2024 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | new | - | 11,193 | 11,193 | -% |
May 01, 2024 | CONCOURSE FINANCIAL GROUP SECURITIES, INC. | sold off | - | - | - | -% |
Unveiling Virios Therapeutics, LLC's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Virios Therapeutics, LLC)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 49.2B | 6.8B | -8.24 | 7.18 | ||||
HILS | 22.5B | 216.3K | -2.5K | 104.0K | ||||
ALNY | 19.0B | 2.0B | -57.12 | 9.47 | ||||
BMRN | 15.3B | 2.5B | 74.39 | 6.18 | ||||
INCY | 12.9B | 3.8B | 17.35 | 3.43 | ||||
MID-CAP | ||||||||
BBIO | 5.3B | 107.9M | -9.76 | 48.09 | ||||
APLS | 5.2B | 524.1M | -12.51 | 9.96 | ||||
AXSM | 3.6B | 251.0M | -12.12 | 14.31 | ||||
ARWR | 2.7B | 240.7M | -5.82 | 12.77 | ||||
ACAD | 2.5B | 813.8M | -1.5K | 3.08 | ||||
SMALL-CAP | ||||||||
CPRX | 1.9B | 411.3M | 29.91 | 4.73 | ||||
NVAX | 1.9B | 996.6M | -4.75 | 1.9 | ||||
CRBP | 456.3M | 881.7K | -13.52 | 481.06 | ||||
INO | 297.2M | 4.9M | -2.38 | 61.07 | ||||
IBIO | 16.2M | 2.1M | -0.7 | 7.61 |
Virios Therapeutics, LLC News
Balance Sheet | |||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 |
Assets | -22.6% | 3,225 | 4,165 | 5,249 | 5,212 | 6,521 | 8,370 | 10,858 | 9,040 | 12,550 | 15,777 | 20,107 | 23,765 | 28,275 | 31,473 |
Current Assets | -22.6% | 3,225 | 4,165 | 5,249 | 5,212 | 6,521 | 8,370 | 10,858 | 9,040 | 12,550 | 15,777 | 20,107 | 23,765 | 28,275 | 31,473 |
Cash Equivalents | -28.3% | 2,380 | 3,317 | 4,786 | 4,590 | 5,333 | 7,031 | 9,788 | 7,695 | 11,352 | 14,008 | 19,186 | 21,835 | 24,586 | 29,795 |
Liabilities | 59.0% | 570 | 359 | 487 | 520 | 549 | 1,043 | 1,633 | 1,898 | 1,877 | 1,276 | 1,227 | 906 | 1,167 | 1,532 |
Current Liabilities | 59.0% | 570 | 359 | 487 | 520 | 549 | 1,043 | 1,633 | 1,898 | 1,877 | 1,276 | 1,227 | 906 | 1,167 | 1,532 |
Shareholder's Equity | -30.3% | 2,655 | 3,807 | 4,762 | 4,692 | 5,971 | 7,326 | 9,225 | 7,142 | 10,673 | 14,501 | 18,880 | 22,859 | 27,107 | 29,941 |
Retained Earnings | -2.1% | -62,760 | -61,469 | -60,366 | -59,130 | -57,690 | -56,173 | -54,128 | -51,552 | -47,885 | -43,925 | -39,414 | -35,300 | -31,000 | -27,965 |
Additional Paid-In Capital | 0.2% | 65,712 | 65,573 | 65,425 | 64,113 | 63,660 | 63,498 | 63,352 | 58,694 | 58,558 | 58,426 | 58,294 | 58,162 | 58,128 | 57,905 |
Shares Outstanding | 0% | 19,258 | 19,258 | 19,258 | 18,330 | 18,330 | 18,330 | 9,200 | 8,330 | 8,330 | 8,330 | 8,330 | 8,328 | - | - |
Float | - | - | - | - | 24,372 | - | - | - | 31,229 | - | - | - | 46,802 | - | - |
Cashflow (Quarterly) | ||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 |
Cashflow From Operations | 36.2% | -937 | -1,469 | -960 | -742 | -1,698 | -2,671 | -2,483 | -3,657 | -2,656 | -5,178 | -2,648 | -2,750 | -5,112 | -2,286 | -558 | -772 | -277 |
Share Based Compensation | -6.3% | 139 | 148 | 148 | 162 | 162 | 150 | 164 | 137 | 132 | 132 | 132 | 34.00 | 25.00 | - | - | - | - |
Cashflow From Financing | - | - | - | - | - | - | -85.99 | - | - | - | - | - | - | -97.60 | 31,583 | 9.00 | 627 | 1,163 |
STATEMENTS OF OPERATIONS - USD ($) | 12 Months Ended | |
---|---|---|
Dec. 31, 2023 | Dec. 31, 2022 | |
Operating expenses: | ||
Research and development | $ 1,728,078 | $ 8,069,628 |
General and administrative expenses | 3,718,841 | 4,245,681 |
Total operating expenses | 5,446,919 | 12,315,309 |
Loss from operations | (5,446,919) | (12,315,309) |
Other income: | ||
Interest income | 150,904 | 67,475 |
Total other income | 150,904 | 67,475 |
Loss before income taxes | (5,296,015) | (12,247,834) |
Net loss | $ (5,296,015) | $ (12,247,834) |
Basic net loss per share (in dollars per share) | $ (0.28) | $ (1.11) |
Diluted net loss per share (in dollars per share) | $ (0.28) | $ (1.11) |
Weighted average number of shares outstanding - basic (in shares) | 18,776,790 | 11,070,116 |
Weighted average number of shares outstanding - diluted (in shares) | 18,776,790 | 11,070,116 |
BALANCE SHEETS - USD ($) | Dec. 31, 2023 | Dec. 31, 2022 |
---|---|---|
Current assets: | ||
Cash | $ 3,316,946 | $ 7,030,992 |
Prepaid expenses and other current assets | 848,496 | 1,338,764 |
Total current assets | 4,165,442 | 8,369,756 |
Total assets | 4,165,442 | 8,369,756 |
Current liabilities: | ||
Accounts payable | 111,913 | 573,164 |
Accrued expenses | 246,635 | 470,098 |
Total current liabilities | 358,548 | 1,043,262 |
Total liabilities | 358,548 | 1,043,262 |
Commitments and contingencies (Note 8) | ||
Stockholders' equity: | ||
Common stock, $0.0001 par value; 43,000,000 shares authorized; 19,450,888 and 19,257,937 shares issued and outstanding at December 31, 2023, respectively; and 18,330,390 shares issued and outstanding at December 31, 2022 | 1,926 | 1,833 |
Preferred stock, $0.0001 par value; 2,000,000 shares authorized, no shares issued and outstanding at December 31, 2023 and 2022 | ||
Additional paid-in capital | 65,573,300 | 63,497,868 |
Accumulated deficit | (61,469,222) | (56,173,207) |
Stockholders' equity before treasury stock | 4,106,004 | 7,326,494 |
Less: Treasury stock, 192,951 shares of common stock at cost | (299,110) | |
Total stockholders' equity | 3,806,894 | 7,326,494 |
Total liabilities and stockholders' equity | $ 4,165,442 | $ 8,369,756 |